A little more than a year ago, I wrote my first article on Trovagene (NASDAQ:TROV). I penned it in response to an SA article I read that touted its "billion-dollar" potential. This was an outlandish claim considering TROV's $51M market cap, a thimble's worth of revenue and four employees. Could the market be this inefficient? After perusing the company's amateurish website and reading about the Xenomics flame out, I concluded that the bullish author was either a paid promoter, a long trying desperately to create support for his losing position or a connoisseur of psilocybin mushrooms. There was no evidence that the company would be able to monetize its patents on nucleic acid testing in urine. In my...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|